Methods for treating cancer using ephrin type-A receptor 10 antibodies conjugated to cytotoxic agents
AssigneeOxford Biotherapeutics Ltd
InventorsChristian Rohlff, Alasdair Stamps
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer or pancreatic cancer, for monitoring the effectiveness of bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer or pancreatic cancer treatment, and for drug development based on Ephrin Type-A Receptor 10 Protein.
Claims2
A method for treating a cancer wherein Ephrin type-A receptor 10 is overexpressed and the cancers are selected from bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer or pancreatic cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an antibody that specifically binds to Ephrin type-A receptor 10, wherein said antibody comprises a conjugated cytotoxic agent, and a pharmaceutically acceptable diluent or carrier wherein said treatment is cytotoxicity.
Dependencies are inferred from the claim text.